Journal Article
. 2016 Feb; 17(3):299-308.
doi: 10.1016/S1470-2045(15)00544-6.

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Scott Antonia 1 Sarah B Goldberg 2 Ani Balmanoukian 3 Jamie E Chaft 4 Rachel E Sanborn 5 Ashok Gupta 6 Rajesh Narwal 6 Keith Steele 6 Yu Gu 6 Joyson J Karakunnel 6 Naiyer A Rizvi 7 
  • PMID: 26858122
  •     16 References
  •     241 citations


Background: PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab might provide greater antitumour activity than either drug alone. We aimed to assess durvalumab plus tremelimumab in patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC).

Methods: We did a multicentre, non-randomised, open-label, phase 1b study at five cancer centres in the USA. We enrolled immunotherapy-naive patients aged 18 years or older with confirmed locally advanced or metastatic NSCLC. We gave patients durvalumab in doses of 3 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg every 4 weeks, or 10 mg/kg every 2 weeks, and tremelimumab in doses of 1 mg/kg, 3 mg/kg, or 10 mg/kg every 4 weeks for six doses then every 12 weeks for three doses. The primary endpoint of the dose-escalation phase was safety. Safety analyses were based on the as-treated population. The dose-expansion phase of the study is ongoing. This study is registered with, number NCT02000947.

Findings: Between Oct 28, 2013, and April 1, 2015, 102 patients were enrolled into the dose-escalation phase and received treatment. At the time of this analysis (June 1, 2015), median follow-up was 18·8 weeks (IQR 11-33). The maximum tolerated dose was exceeded in the cohort receiving durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg, with two (30%) of six patients having a dose-limiting toxicity (one grade 3 increased aspartate aminotransferase and alanine aminotransferase and one grade 4 increased lipase). The most frequent treatment-related grade 3 and 4 adverse events were diarrhoea (11 [11%]), colitis (nine [9%]), and increased lipase (eight [8%]). Discontinuations attributable to treatment-related adverse events occurred in 29 (28%) of 102 patients. Treatment-related serious adverse events occurred in 37 (36%) of 102 patients. 22 patients died during the study, and three deaths were related to treatment. The treatment-related deaths were due to complications arising from myasthenia gravis (durvalumab 10 mg/kg every 4 weeks plus tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg), and neuromuscular disorder (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg). Evidence of clinical activity was noted both in patients with PD-L1-positive tumours and in those with PD-L1-negative tumours. Investigator-reported confirmed objective responses were achieved by six (23%, 95% CI 9-44) of 26 patients in the combined tremelimumab 1 mg/kg cohort, comprising two (22%, 95% CI 3-60) of nine patients with PD-L1-positive tumours and four (29%, 95% CI 8-58) of 14 patients with PD-L1-negative tumours, including those with no PD-L1 staining (four [40%, 95% CI 12-74] of ten patients).

Interpretation: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg showed a manageable tolerability profile, with antitumour activity irrespective of PD-L1 status, and was selected as the dose for phase 3 studies, which are ongoing.

Funding: MedImmune.

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, +13 authors, J Verweij.
Eur J Cancer, 2008 Dec 23; 45(2). PMID: 19097774
Highly Cited.
Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer—review of current data.
Mark S Swanson, Uttam K Sinha.
Oral Oncol, 2014 Dec 03; 51(1). PMID: 25459157
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
Antoni Ribas, Luis H Camacho, +10 authors, Jesus Gomez-Navarro.
J Clin Oncol, 2005 Oct 06; 23(35). PMID: 16204013
Highly Cited.
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.
Zhen-Kui Pan, Feng Ye, +2 authors, Jing-Xun Wu.
J Thorac Dis, 2015 Apr 30; 7(3). PMID: 25922726    Free PMC article.
Highly Cited.
B7-DC regulates asthmatic response by an IFN-gamma-dependent mechanism.
Koichiro Matsumoto, Hiromasa Inoue, +12 authors, Yoichi Nakanishi.
J Immunol, 2004 Feb 07; 172(4). PMID: 14764726
Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.
Pia Kvistborg, Daisy Philips, +13 authors, Ton N Schumacher.
Sci Transl Med, 2014 Sep 19; 6(254). PMID: 25232180
Highly Cited.
B7-DC induced by IL-13 works as a feedback regulator in the effector phase of allergic asthma.
Koichiro Matsumoto, Satoru Fukuyama, +13 authors, Hiromasa Inoue.
Biochem Biophys Res Commun, 2007 Nov 06; 365(1). PMID: 17981145
Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Ross Stewart, Michelle Morrow, +18 authors, Matthew McCourt.
Cancer Immunol Res, 2015 May 07; 3(9). PMID: 25943534
Highly Cited.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, Vanna Chiarion-Sileni, +28 authors, Jedd D Wolchok.
N Engl J Med, 2015 Jun 02; 373(1). PMID: 26027431    Free PMC article.
Highly Cited.
Nivolumab plus ipilimumab in advanced melanoma.
Jedd D Wolchok, Harriet Kluger, +21 authors, Mario Sznol.
N Engl J Med, 2013 Jun 04; 369(2). PMID: 23724867    Free PMC article.
Highly Cited.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, +22 authors, David R Spigel.
N Engl J Med, 2015 Jun 02; 373(2). PMID: 26028407    Free PMC article.
Highly Cited.
Immuno-oncology combinations: a review of clinical experience and future prospects.
Scott J Antonia, James Larkin, Paolo A Ascierto.
Clin Cancer Res, 2014 Oct 25; 20(24). PMID: 25341541
Tremelimumab: a review of development to date in solid tumors.
Ahmad A Tarhini.
Immunotherapy, 2013 Mar 01; 5(3). PMID: 23444951
Innate and adaptive immune cells in the tumor microenvironment.
Thomas F Gajewski, Hans Schreiber, Yang-Xin Fu.
Nat Immunol, 2013 Sep 21; 14(10). PMID: 24048123    Free PMC article.
Highly Cited. Review.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Naiyer A Rizvi, Julien Mazières, +27 authors, Suresh S Ramalingam.
Lancet Oncol, 2015 Feb 24; 16(3). PMID: 25704439    Free PMC article.
Highly Cited.
A parallel phase I/II clinical trial design for combination therapies.
Xuelin Huang, Swati Biswas, +2 authors, Donald A Berry.
Biometrics, 2007 Aug 11; 63(2). PMID: 17688495
Into the Clinic With Nivolumab and Pembrolizumab.
Catherine A Shu, Naiyer A Rizvi.
Oncologist, 2016 Mar 31; 21(5). PMID: 27026678    Free PMC article.
The role of neoantigens in response to immune checkpoint blockade.
Nadeem Riaz, Luc Morris, +3 authors, Timothy A Chan.
Int Immunol, 2016 Apr 07; 28(8). PMID: 27048318    Free PMC article.
Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Weijie Ma, Barbara M Gilligan, Jianda Yuan, Tianhong Li.
J Hematol Oncol, 2016 May 29; 9(1). PMID: 27234522    Free PMC article.
Highly Cited. Review.
A second chance for telomerase reverse transcriptase in anticancer immunotherapy.
Maurizio Zanetti.
Nat Rev Clin Oncol, 2016 Nov 03; 14(2). PMID: 27245281
Chemotherapy remains an essential element of personalized care for persons with lung cancers.
M D Hellmann, B T Li, J E Chaft, M G Kris.
Ann Oncol, 2016 Jul 28; 27(10). PMID: 27456296    Free PMC article.
Immune Checkpoint Blockade: A New Era for Non-Small Cell Lung Cancer.
Raffaele Califano, Keith Kerr, +4 authors, Antonio Rossi.
Curr Oncol Rep, 2016 Aug 04; 18(9). PMID: 27484062
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Claud Grigg, Naiyer A Rizvi.
J Immunother Cancer, 2016 Aug 18; 4. PMID: 27532023    Free PMC article.
Highly Cited. Review.
Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
Grainne M O'Kane, Catherine Labbé, +3 authors, Natasha B Leighl.
Oncologist, 2016 Aug 19; 22(1). PMID: 27534573    Free PMC article.
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Benjamin Herzberg, Meghan J Campo, Justin F Gainor.
Oncologist, 2016 Aug 19; 22(1). PMID: 27534574    Free PMC article.
Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us?
Michiel van der Vlist, Jurgen Kuball, Timothy R D Radstake, Linde Meyaard.
Nat Rev Rheumatol, 2016 Aug 20; 12(10). PMID: 27539666
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment.
Hazem El-Osta, Kamran Shahid, Glenn M Mills, Prakash Peddi.
Onco Targets Ther, 2016 Aug 31; 9. PMID: 27574451    Free PMC article.
Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells.
Liyun Miao, Zhen Huang, +7 authors, Yongsheng Wang.
Oncotarget, 2016 Sep 01; 7(42). PMID: 27577075    Free PMC article.
Update in Lung Cancer 2015.
Avrum Spira, Balazs Halmos, Charles A Powell.
Am J Respir Crit Care Med, 2016 Sep 16; 194(6). PMID: 27628077    Free PMC article.
Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy.
Jarushka Naidoo, Xuan Wang, +26 authors, Matthew D Hellmann.
J Clin Oncol, 2016 Sep 21; 35(7). PMID: 27646942    Free PMC article.
Highly Cited.
Checkpoint inhibitors in lung cancer: latest developments and clinical potential.
Gustavo Schvartsman, Renata Ferrarotto, Erminia Massarelli.
Ther Adv Med Oncol, 2016 Nov 02; 8(6). PMID: 27800034    Free PMC article.
Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment.
Andrea Botticelli, Ilaria Zizzari, +6 authors, Paolo Marchetti.
Oncotarget, 2016 Nov 03; 8(5). PMID: 27806346    Free PMC article.
Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors.
Ana P S Silva, Priscila V Coelho, Maristella Anazetti, Patricia U Simioni.
Hum Vaccin Immunother, 2016 Nov 11; 13(4). PMID: 27831000    Free PMC article.
Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.
Matthew D Hellmann, Naiyer A Rizvi, +14 authors, Scott J Antonia.
Lancet Oncol, 2016 Dec 10; 18(1). PMID: 27932067    Free PMC article.
Highly Cited.
Emerging therapeutic agents for lung cancer.
Bhagirathbhai Dholaria, William Hammond, Amanda Shreders, Yanyan Lou.
J Hematol Oncol, 2016 Dec 13; 9(1). PMID: 27938382    Free PMC article.
Highly Cited. Review.
T cell exhaustion: from pathophysiological basics to tumor immunotherapy.
Kemal Catakovic, Eckhard Klieser, Daniel Neureiter, Roland Geisberger.
Cell Commun Signal, 2017 Jan 12; 15(1). PMID: 28073373    Free PMC article.
Highly Cited. Review.
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
David J Byun, Jedd D Wolchok, Lynne M Rosenberg, Monica Girotra.
Nat Rev Endocrinol, 2017 Jan 21; 13(4). PMID: 28106152    Free PMC article.
Highly Cited. Review.
Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.
Grainne M O'Kane, Natasha B Leighl.
Transl Lung Cancer Res, 2017 Feb 06; 5(6). PMID: 28149757    Free PMC article.
Combination immunotherapy: a road map.
Patrick A Ott, F Stephen Hodi, +2 authors, Jedd D Wolchok.
J Immunother Cancer, 2017 Feb 28; 5. PMID: 28239469    Free PMC article.
Highly Cited. Review.
Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report.
Hong Li, Weijie Ma, +7 authors, Tianhong Li.
J Hematol Oncol, 2017 Mar 02; 10(1). PMID: 28245875    Free PMC article.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lesley Seymour, Jan Bogaerts, +16 authors, RECIST working group.
Lancet Oncol, 2017 Mar 09; 18(3). PMID: 28271869    Free PMC article.
Highly Cited. Review.
Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.
Ahmet Murat Aydin, Solomon L Woldu, +5 authors, Laura-Maria Krabbe.
Onco Targets Ther, 2017 Mar 24; 10. PMID: 28331342    Free PMC article.
Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.
James L Gulley, Arun Rajan, +11 authors, Karen Kelly.
Lancet Oncol, 2017 Apr 05; 18(5). PMID: 28373005    Free PMC article.
Highly Cited.
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.
Paul C Tumeh, Matthew D Hellmann, +31 authors, Adil Daud.
Cancer Immunol Res, 2017 Apr 16; 5(5). PMID: 28411193    Free PMC article.
Highly Cited.
Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.
Marco A J Iafolla, Rosalyn A Juergens.
Front Oncol, 2017 Apr 22; 7. PMID: 28428947    Free PMC article.
Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.
Kamran A Ahmed, Sungjune Kim, +12 authors, Bradford A Perez.
J Neurooncol, 2017 May 04; 133(2). PMID: 28466250
Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Jung-Min Lee, Ashley Cimino-Mathews, +16 authors, Elise C Kohn.
J Clin Oncol, 2017 May 05; 35(19). PMID: 28471727    Free PMC article.
Highly Cited.
Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab.
Udupi A Ramagopal, Weifeng Liu, +10 authors, Steven C Almo.
Proc Natl Acad Sci U S A, 2017 May 10; 114(21). PMID: 28484017    Free PMC article.
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab.
Shuguang Tan, Kefang Liu, +4 authors, Jianxun Qi.
Protein Cell, 2017 May 11; 9(1). PMID: 28488247    Free PMC article.
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma.
Masha Zeltsman, Jordan Dozier, +2 authors, Prasad S Adusumilli.
Transl Res, 2017 May 16; 187. PMID: 28502785    Free PMC article.
A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer.
William Carrera, Brandon J Baartman, Gregory Kosmorsky.
Neuroophthalmology, 2017 May 18; 41(3). PMID: 28512504    Free PMC article.
Current state of immunotherapy for non-small cell lung cancer.
Jyoti Malhotra, Salma K Jabbour, Joseph Aisner.
Transl Lung Cancer Res, 2017 May 23; 6(2). PMID: 28529902    Free PMC article.
Highly Cited. Review.
Delivering safer immunotherapies for cancer.
Lauren Milling, Yuan Zhang, Darrell J Irvine.
Adv Drug Deliv Rev, 2017 May 27; 114. PMID: 28545888    Free PMC article.
Highly Cited. Review.
Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer.
Emma Nolan, Peter Savas, +13 authors, Geoffrey J Lindeman.
Sci Transl Med, 2017 Jun 09; 9(393). PMID: 28592566    Free PMC article.
Highly Cited.
Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer.
Olivier Bylicki, Nicolas Paleiron, +6 authors, Christos Chouaid.
Target Oncol, 2017 Jun 19; 12(5). PMID: 28624922
[Prospect and Current Situation of Immune Checkpoint Inhibitors 
in First-line Treatment in Advanced Non-small Cell Lung Cancer Patients].
Haiyang Wang, Xiaoqing Yu, Yun Fan.
Zhongguo Fei Ai Za Zhi, 2017 Jun 24; 20(6). PMID: 28641702    Free PMC article.
Durvalumab: First Global Approval.
Yahiya Y Syed.
Drugs, 2017 Jun 24; 77(12). PMID: 28643244    Free PMC article.
PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability.
Hans Brunnström, Anna Johansson, +6 authors, Patrick Micke.
Mod Pathol, 2017 Jul 01; 30(10). PMID: 28664936
Highly Cited.
Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China.
Si-Yang Liu, Yi-Long Wu.
J Hematol Oncol, 2017 Jul 07; 10(1). PMID: 28679395    Free PMC article.
Targeted therapies for renal cell carcinoma.
Edwin M Posadas, Suwicha Limvorasak, Robert A Figlin.
Nat Rev Nephrol, 2017 Jul 12; 13(8). PMID: 28691713
Highly Cited. Review.
Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
Cesare Gridelli, Andrea Ardizzoni, +5 authors, Filippo De Marinis.
Transl Lung Cancer Res, 2017 Jul 18; 6(3). PMID: 28713682    Free PMC article.
Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.
Sooraj John, Scott J Antonia, +4 authors, Ben C Creelan.
J Immunother Cancer, 2017 Jul 19; 5(1). PMID: 28716137    Free PMC article.
Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives.
Xiongwen Ran, Kai Yang.
Drug Des Devel Ther, 2017 Jul 20; 11. PMID: 28721019    Free PMC article.
Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma.
Natasha Lakin, Robert Rulach, Stefan Nowicki, Kathreena M Kurian.
Front Oncol, 2017 Jul 22; 7. PMID: 28730140    Free PMC article.
Treating EGFR mutation resistance in non-small cell lung cancer - role of osimertinib.
Valentina Mazza, Federico Cappuzzo.
Appl Clin Genet, 2017 Aug 11; 10. PMID: 28794650    Free PMC article.
EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR wild-type pre-treated advanced nonsmall cell lung cancer in daily practice.
Pascale Tomasini, Solenn Brosseau, +17 authors, Fabrice Barlesi.
Eur Respir J, 2017 Aug 12; 50(2). PMID: 28798090
Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.
Karim Rihawi, Francesco Gelsomino, +4 authors, Andrea Ardizzoni.
Ther Adv Respir Dis, 2017 Aug 19; 11(9). PMID: 28818019    Free PMC article.
Functional Expression of Programmed Death-Ligand 1 (B7-H1) by Immune Cells and Tumor Cells.
Rachel M Gibbons Johnson, Haidong Dong.
Front Immunol, 2017 Aug 30; 8. PMID: 28848559    Free PMC article.
Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.
Ece Esin.
Biomed Res Int, 2017 Aug 30; 2017. PMID: 28848761    Free PMC article.
From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely.
Daphne Day, Arta M Monjazeb, +4 authors, Marcus O Butler.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864726    Free PMC article.
Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities.
Christina S Baik, Eric H Rubin, +5 authors, Laura Q M Chow.
Clin Cancer Res, 2017 Sep 03; 23(17). PMID: 28864727    Free PMC article.
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome.
Hashem O Alsaab, Samaresh Sau, +4 authors, Arun K Iyer.
Front Pharmacol, 2017 Sep 08; 8. PMID: 28878676    Free PMC article.
Highly Cited. Review.
Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases.
Manuel D Keller, Christina Neppl, +4 authors, Sabina Berezowska.
Mod Pathol, 2017 Sep 09; 31(1). PMID: 28884747
Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy.
Sulsal Haque, Mahender Yellu, Jaskirat Randhawa, Nooshin Hashemi-Sadraei.
Drug Des Devel Ther, 2017 Sep 19; 11. PMID: 28919706    Free PMC article.
B cells in the pathophysiology of myasthenia gravis.
John S Yi, Jeffrey T Guptill, +2 authors, Kevin C O'Connor.
Muscle Nerve, 2017 Sep 25; 57(2). PMID: 28940642    Free PMC article.
4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer.
Donastas Sakellariou-Thompson, Marie-Andrée Forget, +20 authors, Chantale Bernatchez.
Clin Cancer Res, 2017 Sep 28; 23(23). PMID: 28947567    Free PMC article.
Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies.
Mengnan He, Yan Chai, +6 authors, George F Gao.
Oncotarget, 2017 Oct 06; 8(40). PMID: 28978021    Free PMC article.
Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
Scott Gettinger, Jungmin Choi, +23 authors, Katerina Politi.
Cancer Discov, 2017 Oct 14; 7(12). PMID: 29025772    Free PMC article.
Highly Cited.
Clinical features, predictive correlates, and pathophysiology of immune-related adverse events in immune checkpoint inhibitor treatments in cancer: a short review.
Jennifer M Yoest.
Immunotargets Ther, 2017 Oct 27; 6. PMID: 29067284    Free PMC article.
Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a meta-analysis.
Yongxun Zhuan-Sun, Fengting Huang, +4 authors, Shineng Zhang.
Onco Targets Ther, 2017 Oct 31; 10. PMID: 29081663    Free PMC article.
PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer.
Katerina Ancevski Hunter, Mark A Socinski, Liza C Villaruz.
Mol Diagn Ther, 2017 Nov 10; 22(1). PMID: 29119407    Free PMC article.
Immune checkpoint inhibitors: new strategies to checkmate cancer.
R A M Wilson, T R J Evans, A R Fraser, R J B Nibbs.
Clin Exp Immunol, 2017 Nov 16; 191(2). PMID: 29139554    Free PMC article.
Trial Watch: Adoptively transferred cells for anticancer immunotherapy.
Carole Fournier, François Martin, +3 authors, Lionel Apetoh.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147628    Free PMC article.
Trial watch: Immune checkpoint blockers for cancer therapy.
Claire Vanpouille-Box, Claire Lhuillier, +10 authors, Lorenzo Galluzzi.
Oncoimmunology, 2017 Nov 18; 6(11). PMID: 29147629    Free PMC article.
Highly Cited. Review.
CD80 Expressed by CD8+ T Cells Contributes to PD-L1-Induced Apoptosis of Activated CD8+ T Cells.
Meagan R Rollins, Rachel M Gibbons Johnson.
J Immunol Res, 2017 Nov 29; 2017. PMID: 29181416    Free PMC article.
Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition.
Arlene Siefker-Radtke, Brendan Curti.
Nat Rev Urol, 2017 Dec 06; 15(2). PMID: 29205200
Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets.
Pedro Nazareth Aguiar, Ramon Andrade De Mello, +4 authors, Gilberto de Lima Lopes.
ESMO Open, 2017 Dec 07; 2(3). PMID: 29209522    Free PMC article.
Soluble PD-1 and PD-L1: predictive and prognostic significance in cancer.
Xinxin Zhu, Jinghe Lang.
Oncotarget, 2017 Dec 13; 8(57). PMID: 29228642    Free PMC article.
Highly Cited. Review.
A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer.
Rachel E Sanborn, Helen J Ross, +12 authors, Bernard A Fox.
J Immunother Cancer, 2017 Dec 21; 5(1). PMID: 29258618    Free PMC article.
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Chi Young Jung, Scott J Antonia.
Tuberc Respir Dis (Seoul), 2018 Jan 15; 81(1). PMID: 29332322    Free PMC article.
PD-1/PD-L1 Axis in Lung Cancer.
Fernando C Santini, Matthew D Hellmann.
Cancer J, 2018 Jan 24; 24(1). PMID: 29360723    Free PMC article.
The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?
Amy L Cummings, Edward B Garon.
Cancer Biol Med, 2018 Jan 27; 14(4). PMID: 29372100    Free PMC article.
Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).
Irene Moya-Horno, Santiago Viteri, Niki Karachaliou, Rafael Rosell.
Ther Adv Med Oncol, 2018 Feb 01; 10. PMID: 29383034    Free PMC article.
Highly Cited. Review.
Role of immune-checkpoint inhibitors in lung cancer.
Prantesh Jain, Chhavi Jain, Vamsidhar Velcheti.
Ther Adv Respir Dis, 2018 Feb 02; 12. PMID: 29385894    Free PMC article.
Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.
Christophoros Astaras, Rita de Micheli, +2 authors, Andreas F Hottinger.
Curr Neurol Neurosci Rep, 2018 Feb 03; 18(1). PMID: 29392441
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy.
Christian Manegold, Alex Adjei, +19 authors, Caicun Zhou.
ESMO Open, 2018 Feb 13; 1(6). PMID: 29435365    Free PMC article.
Immune Checkpoint Blockade: The New Frontier in Cancer Treatment.
Jeffrey M Clarke, Daniel J George, Stacey Lisi, April K S Salama.
Target Oncol, 2018 Feb 15; 13(1). PMID: 29441437
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice.
Xuexiang Du, Mingyue Liu, +8 authors, Pan Zheng.
Cell Res, 2018 Feb 22; 28(4). PMID: 29463898    Free PMC article.
Highly Cited.
Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials.
Alberto Carretero-González, David Lora, +6 authors, Guillermo de Velasco.
Oncotarget, 2018 Mar 02; 9(9). PMID: 29492229    Free PMC article.
PACIFIC trial: new perspectives for immunotherapy in lung cancer.
Francesco Agustoni, Fred R Hirsch.
Transl Lung Cancer Res, 2018 Mar 14; 7(Suppl 1). PMID: 29531898    Free PMC article.
Putting the brakes on CTLA-4 inhibition in lung cancer?
Meghan J Mooradian, Justin F Gainor.
Transl Lung Cancer Res, 2018 Mar 14; 7(Suppl 1). PMID: 29531902    Free PMC article.
Immunotherapy in treatment naïve advanced non-small cell lung cancer.
Vinicius Ernani, Apar Kishor Ganti.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593887    Free PMC article.
Immunotherapy combination strategies (non-chemotherapy) in non-small cell lung cancer.
Sandrine Niyongere, Andreas Saltos, Jhanelle E Gray.
J Thorac Dis, 2018 Mar 30; 10(Suppl 3). PMID: 29593889    Free PMC article.
Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody.
Randi B Gombos, Ana Gonzalez, +24 authors, Nicholas S Wilson.
PLoS One, 2018 Apr 05; 13(4). PMID: 29617360    Free PMC article.
T Cell Calcium Signaling Regulation by the Co-Receptor CD5.
Claudia M Tellez Freitas, Deborah K Johnson, K Scott Weber.
Int J Mol Sci, 2018 Apr 28; 19(5). PMID: 29701673    Free PMC article.
Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism.
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe.
Endocr Connect, 2018 May 10; 7(5). PMID: 29739808    Free PMC article.
Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.
Michael R Shafique, Lary A Robinson, Scott Antonia.
Cancer Manag Res, 2018 May 16; 10. PMID: 29760563    Free PMC article.
Seronegative antibody-mediated neurology after immune checkpoint inhibitors.
Robert Wilson, David A Menassa, +11 authors, Sarosh R Irani.
Ann Clin Transl Neurol, 2018 May 16; 5(5). PMID: 29761126    Free PMC article.
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Young Kwang Chae, Ayush Arya, +4 authors, Francis Giles.
J Immunother Cancer, 2018 May 18; 6(1). PMID: 29769148    Free PMC article.
Highly Cited. Review.
Durvalumab after chemoradiotherapy in stage III non-small cell lung cancer.
Pascale Tomasini, Laurent Greillier, +2 authors, Fabrice Barlesi.
J Thorac Dis, 2018 Jun 01; 10(Suppl 9). PMID: 29850182    Free PMC article.
The emerging treatment landscape of advanced non-small cell lung cancer.
Panagiota Economopoulou, Giannis Mountzios.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862227    Free PMC article.
Breakthroughs in the treatment of advanced squamous-cell NSCLC: not the neglected sibling anymore?
Georgios Tsironis, Dimitrios C Ziogas, +4 authors, Meletios-Athanasios Dimopoulos.
Ann Transl Med, 2018 Jun 05; 6(8). PMID: 29862232    Free PMC article.
Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer.
A Pabani, C A Butts.
Curr Oncol, 2018 Jun 19; 25(Suppl 1). PMID: 29910652    Free PMC article.
Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer.
Jean-David Fumet, Nicolas Isambert, +6 authors, Francois Ghiringhelli.
ESMO Open, 2018 Jun 27; 3(4). PMID: 29942666    Free PMC article.
Advanced non-small cell lung cancer: the role of PD-L1 inhibitors.
David F Heigener, Martin Reck.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951298    Free PMC article.
Immunotherapy in the Asiatic population: any differences from Caucasian population?
Lunxi Peng, Yi-Long Wu.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951300    Free PMC article.
Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.
Jordi Remon, Laura Mezquita, +2 authors, Noemi Reguart.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951303    Free PMC article.
Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors.
Meng Qiao, Tao Jiang, Caicun Zhou.
J Thorac Dis, 2018 Jun 29; 10(Suppl 13). PMID: 29951304    Free PMC article.
Harmonization of PD-L1 testing in oncology: a Canadian pathology perspective.
D N Ionescu, M R Downes, A Christofides, M S Tsao.
Curr Oncol, 2018 Jul 03; 25(3). PMID: 29962847    Free PMC article.
Safety and efficacy of durvalumab (MEDI4736) in various solid tumors.
Hui Yang, Kai Shen, +3 authors, Xuelei Ma.
Drug Des Devel Ther, 2018 Jul 18; 12. PMID: 30013326    Free PMC article.
A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers.
S N Gettinger, J Choi, +19 authors, K A Schalper.
Nat Commun, 2018 Aug 12; 9(1). PMID: 30097571    Free PMC article.
Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
Hongshu Sui, Ningxia Ma, +4 authors, Jiali Yang.
J Immunol Res, 2018 Aug 31; 2018. PMID: 30159341    Free PMC article.
Highly Cited. Review.
Immuno-Oncology: Emerging Targets and Combination Therapies.
Henry T Marshall, Mustafa B A Djamgoz.
Front Oncol, 2018 Sep 08; 8. PMID: 30191140    Free PMC article.
Highly Cited. Review.
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
Nicolas Villanueva, Lyudmila Bazhenova.
Ther Adv Respir Dis, 2018 Sep 15; 12. PMID: 30215300    Free PMC article.
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma.
Jun Zhang, L Jeffrey Medeiros, Ken H Young.
Front Oncol, 2018 Sep 27; 8. PMID: 30250823    Free PMC article.
Durvalumab in NSCLC: latest evidence and clinical potential.
Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares.
Ther Adv Med Oncol, 2018 Oct 23; 10. PMID: 30344651    Free PMC article.
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
Abhishek Tripathi, Elizabeth R Plimack.
Curr Urol Rep, 2018 Nov 09; 19(12). PMID: 30406502
Anti PD-1 immunotherapy related interstitial lung disease presenting as respiratory failure - A review with case series.
Padmastuti Akella, Sundaravadivel Loganathan, +2 authors, Amos Lal.
Respir Med Case Rep, 2018 Nov 21; 26. PMID: 30456167    Free PMC article.
Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges.
N A Nixon, N Blais, +5 authors, S Verma.
Curr Oncol, 2018 Nov 23; 25(5). PMID: 30464687    Free PMC article.
Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
Lizza E Hendriks, Etienne Rouleau, Benjamin Besse.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505709    Free PMC article.
Recent developments in limited stage small cell lung cancer.
Kristin A Higgins, Sophia Gorgens, Lisa J Sudmeier, Corinne Faivre-Finn.
Transl Lung Cancer Res, 2019 Nov 02; 8(Suppl 2). PMID: 31673519    Free PMC article.
KEYNOTE-021 cohorts D and H suggest modest benefit in combining ipilimumab with pembrolizumab in second-line or later advanced non-small cell lung cancer treatment.
Amy Lauren Cummings, Kate M Santoso, Jonathan W Goldman.
Transl Lung Cancer Res, 2019 Nov 19; 8(5). PMID: 31737507    Free PMC article.
Antitumor Activity and Treatment-Related Toxicity Associated With Nivolumab Plus Ipilimumab in Advanced Malignancies: A Systematic Review and Meta-Analysis.
Hang Xu, Ping Tan, +5 authors, Qiang Wei.
Front Pharmacol, 2019 Nov 22; 10. PMID: 31749704    Free PMC article.
Systematic Review.
Combination of PD-L1 expression and NLR as prognostic marker in patients with surgically resected non-small cell lung cancer.
Xinyue Wang, Lianjing Cao, +3 authors, Richeng Jiang.
J Cancer, 2019 Nov 30; 10(26). PMID: 31777599    Free PMC article.
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.
Molly A Taylor, Adina M Hughes, +10 authors, Elizabeth L Hardaker.
J Immunother Cancer, 2019 Nov 30; 7(1). PMID: 31779705    Free PMC article.
Neurological Immune Related Adverse Events Associated with Nivolumab, Ipilimumab, and Pembrolizumab Therapy-Review of the Literature and Future Outlook.
Nora Möhn, Gernot Beutel, +3 authors, Thomas Skripuletz.
J Clin Med, 2019 Oct 28; 8(11). PMID: 31653079    Free PMC article.
Development of therapeutic antibodies for the treatment of diseases.
Ruei-Min Lu, Yu-Chyi Hwang, +4 authors, Han-Chung Wu.
J Biomed Sci, 2020 Jan 03; 27(1). PMID: 31894001    Free PMC article.
Long non-coding RNA LINC00243 promotes proliferation and glycolysis in non-small cell lung cancer cells by positively regulating PDK4 through sponging miR-507.
Xuegang Feng, Shengsheng Yang.
Mol Cell Biochem, 2019 Oct 09; 463(1-2). PMID: 31595421
Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.
Barbara Melosky, Rosalyn Juergens, +5 authors, Quincy Chu.
Oncologist, 2019 May 30; 25(1). PMID: 31138727    Free PMC article.
Uniportal thoracoscopic pulmonary lobectomy in the treatment of Lung Cancer.
Jinying Zhang, Haixia Zhao, +2 authors, Yuzhen Sun.
Pak J Med Sci, 2020 Feb 18; 36(2). PMID: 32063956    Free PMC article.
Fatal Adverse Events Associated With Programmed Cell Death Ligand 1 Inhibitors: A Systematic Review and Meta-Analysis.
Xuewen Wang, Shijie Wu, +4 authors, Xiong Chen.
Front Pharmacol, 2020 Feb 23; 11. PMID: 32076409    Free PMC article.
Systematic Review.
Cancer immunotherapy with immunoadjuvants, nanoparticles, and checkpoint inhibitors: Recent progress and challenges in treatment and tracking response to immunotherapy.
Michael-Joseph Gorbet, Ashish Ranjan.
Pharmacol Ther, 2019 Dec 22; 207. PMID: 31863820    Free PMC article.
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.
Brian P Hobbs, Pedro C Barata, +16 authors, Gary L Rosner.
J Natl Cancer Inst, 2018 Dec 19; 111(2). PMID: 30561713    Free PMC article.
A functional antibody cross-reactive to both human and murine cytotoxic T-lymphocyte-associated protein 4 via binding to an N-glycosylation epitope.
Dong Li, Jing Li, Huanyu Chu, Zhuozhi Wang.
MAbs, 2020 Feb 15; 12(1). PMID: 32054416    Free PMC article.
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy.
Xiaolei Li, Wenhui Song, +2 authors, Weidong Han.
Cell Mol Immunol, 2018 Jul 14; 16(1). PMID: 30002451    Free PMC article.
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.
Lillian L Siu, Caroline Even, +18 authors, Jérôme Fayette.
JAMA Oncol, 2018 Nov 02; 5(2). PMID: 30383184    Free PMC article.
Highly Cited.
Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
Shun Lu, Yongfeng Yu, Yi Yang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819828    Free PMC article.
PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Liliang Xia, Yuanyong Liu, Ying Wang.
Oncologist, 2019 Mar 02; 24(Suppl 1). PMID: 30819829    Free PMC article.
Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.
Jasmine Davda, Paul Declerck, +5 authors, Eugenia Kraynov.
J Immunother Cancer, 2019 Apr 18; 7(1). PMID: 30992085    Free PMC article.
Emerging therapies for non-small cell lung cancer.
Chao Zhang, Natasha B Leighl, Yi-Long Wu, Wen-Zhao Zhong.
J Hematol Oncol, 2019 Apr 27; 12(1). PMID: 31023335    Free PMC article.
Highly Cited. Review.
Patient-Derived Non-Muscular Invasive Bladder Cancer Xenografts of Main Molecular Subtypes of the Tumor for Anti-Pd-l1 Treatment Assessment.
Ekaterina Blinova, Dmitry Roshchin, +9 authors, Andrey Kaprin.
Cells, 2019 Jun 05; 8(6). PMID: 31159302    Free PMC article.
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
Diego Signorelli, Patrizia Giannatempo, +11 authors, Immune-Oncology YOUNG Group.
Biomed Res Int, 2019 Jun 11; 2019. PMID: 31179334    Free PMC article.
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
Alexander Haragan, John K Field, +3 authors, John R Gosney.
Lung Cancer, 2019 Jul 20; 134. PMID: 31320000    Free PMC article.
Immunosurveillance and Immunoediting of Lung Cancer: Current Perspectives and Challenges.
Kei Kunimasa, Taichiro Goto.
Int J Mol Sci, 2020 Jan 23; 21(2). PMID: 31963413    Free PMC article.
Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
Sonam Puri, Michael Shafique.
Drugs Context, 2020 Mar 12; 9. PMID: 32158484    Free PMC article.
Determinants of Resistance to Checkpoint Inhibitors.
Linda Tran, Dan Theodorescu.
Int J Mol Sci, 2020 Mar 01; 21(5). PMID: 32111080    Free PMC article.
Frontiers of ctDNA, targeted therapies, and immunotherapy in non-small-cell lung cancer.
Chennianci Zhu, Weihao Zhuang, +2 authors, Wen-Bin Ou.
Transl Lung Cancer Res, 2020 Mar 25; 9(1). PMID: 32206559    Free PMC article.
Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis.
Robin Park, Laercio Lopes, +2 authors, Anwaar Saeed.
Front Oncol, 2020 Apr 08; 10. PMID: 32257944    Free PMC article.
Systematic Review.
Immunotherapy: From Advanced NSCLC to Early Stages, an Evolving Concept.
Thierry Berghmans, Valérie Durieux, Lizza E L Hendriks, Anne-Marie Dingemans.
Front Med (Lausanne), 2020 Apr 09; 7. PMID: 32266275    Free PMC article.
Systematic Review.
The Tolerogenic Function of Regulatory T Cells in Pregnancy and Cancer.
Nanna Jørgensen, Gry Persson, Thomas Vauvert F Hviid.
Front Immunol, 2019 May 28; 10. PMID: 31134056    Free PMC article.
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Naiyer A Rizvi, Byoung Chul Cho, +28 authors, MYSTIC Investigators.
JAMA Oncol, 2020 Apr 10; 6(5). PMID: 32271377    Free PMC article.
New Approaches on Cancer Immunotherapy.
Jong-Ho Cha, Li-Chuan Chan, Min Sup Song, Mien-Chie Hung.
Cold Spring Harb Perspect Med, 2019 Oct 17; 10(8). PMID: 31615865    Free PMC article.
Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder.
Bo Wang, Wenwei Pan, +7 authors, Tianxin Lin.
Cancer Sci, 2018 Dec 15; 110(2). PMID: 30548363    Free PMC article.
Tolerability and efficacy of durvalumab in Japanese patients with advanced solid tumors.
Yutaka Fujiwara, Haruo Iguchi, +7 authors, Toshiyuki Kozuki.
Cancer Sci, 2019 Mar 21; 110(5). PMID: 30891877    Free PMC article.
Cancer in the time of COVID-19: expert opinion on how to adapt current practice.
Jo Raskin, Marnix Lebeer, +3 authors, Jan P van Meerbeeck.
Eur Respir J, 2020 Apr 18; 55(5). PMID: 32299866    Free PMC article.
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
Marine Leclerc, Laura Mezquita, +4 authors, Fathia Mami-Chouaib.
Front Immunol, 2019 Jul 25; 10. PMID: 31333652    Free PMC article.
Comparison of programmed death-ligand 1 (PD-L1) immunostain for nonsmall cell lung carcinoma between paired cytological and surgical specimens.
Huihong Xu, Laura Bratton, +2 authors, Zhongren Zhou.
Cytojournal, 2019 Jan 22; 15. PMID: 30662515    Free PMC article.
Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study.
Eric X Chen, Derek J Jonker, +18 authors, Chris J O'Callaghan.
JAMA Oncol, 2020 May 08; 6(6). PMID: 32379280    Free PMC article.
Soluble CD80 Protein Delays Tumor Growth and Promotes Tumor-Infiltrating Lymphocytes.
Lucas A Horn, Tiha M Long, +2 authors, Suzanne Ostrand-Rosenberg.
Cancer Immunol Res, 2017 Nov 11; 6(1). PMID: 29122838    Free PMC article.
Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy.
Donastas Sakellariou-Thompson, Marie-Andrée Forget, +5 authors, Chantale Bernatchez.
Cancer Immunol Immunother, 2019 Oct 12; 68(11). PMID: 31602489    Free PMC article.
Current Clinical Progress of PD-1/PD-L1 Immunotherapy and Potential Combination Treatment in Non-Small Cell Lung Cancer.
Jia-Xin Li, Ju-Min Huang, +4 authors, Pei-Yu Yan.
Integr Cancer Ther, 2019 Dec 17; 18. PMID: 31838881    Free PMC article.
PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake.
Jian-Ye Zhang, Yan-Yan Yan, +2 authors, Li-Wu Fu.
Front Pharmacol, 2020 Jun 13; 11. PMID: 32528284    Free PMC article.
Cancer, immune suppression and Coronavirus Disease-19 (COVID-19): Need to manage drug safety (French Society for Oncology Pharmacy [SFPO] guidelines).
Florian Slimano, Amandine Baudouin, +12 authors, Catherine Rioufol.
Cancer Treat Rev, 2020 Jul 06; 88. PMID: 32623296    Free PMC article.
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.
Omid Kooshkaki, Afshin Derakhshani, +6 authors, Behzad Baradaran.
Int J Mol Sci, 2020 Jun 26; 21(12). PMID: 32580338    Free PMC article.
Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Eileen M O'Reilly, Do-Youn Oh, +11 authors, Philip Agop Philip.
JAMA Oncol, 2019 Jul 19; 5(10). PMID: 31318392    Free PMC article.
Highly Cited.
Durvalumab and tremelimumab combination therapy versus durvalumab or tremelimumab monotherapy for patients with solid tumors: A systematic review and meta-analysis.
Bi-Cheng Wang, Peng-Cheng Li, +2 authors, Quentin Liu.
Medicine (Baltimore), 2020 Jul 16; 99(28). PMID: 32664183    Free PMC article.
Systematic Review.
Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context.
Sneha Gullapalli, Jordi Remon, Lizza E L Hendriks, Gilberto Lopes.
Onco Targets Ther, 2020 Aug 09; 13. PMID: 32764980    Free PMC article.
Immune Checkpoint Inhibitor-Induced Myasthenia Gravis.
Yi-Te Huang, Ya-Ping Chen, +2 authors, Yuan-Ting Sun.
Front Neurol, 2020 Aug 09; 11. PMID: 32765397    Free PMC article.
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity.
Rong Tang, Jin Xu, +6 authors, Si Shi.
J Hematol Oncol, 2020 Aug 12; 13(1). PMID: 32778143    Free PMC article.
Drug-Related Pneumonitis in the Era of Precision Cancer Therapy.
Mizuki Nishino, Hiroto Hatabu, F Stephen Hodi, Nikhil H Ramaiya.
JCO Precis Oncol, 2017 May 26; 1. PMID: 32913972    Free PMC article.
[First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer].
Xiaoxiao Peng, Qing Zhou.
Zhongguo Fei Ai Za Zhi, 2018 Dec 29; 21(12). PMID: 30591101    Free PMC article.
Compare the efficacy and safety of programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors for advanced non-small cell lung cancer: a Bayesian analysis.
Jiaqi Liang, Ming Li, +7 authors, Lijie Tan.
Transl Lung Cancer Res, 2020 Sep 22; 9(4). PMID: 32953506    Free PMC article.
Combination approaches in NSCLC involving immune checkpoint inhibitors.
Surein Arulananda, Gareth Rivalland, Thomas John.
Lung Cancer Manag, 2016 Dec 01; 5(4). PMID: 30643561    Free PMC article.
Engineering Precision Medicine.
Wujin Sun, Junmin Lee, +3 authors, Ali Khademhosseini.
Adv Sci (Weinh), 2019 Jan 16; 6(1). PMID: 30643715    Free PMC article.
PD-L1 and immune infiltrates are differentially expressed in distinct subgroups of gastric cancer.
H K Angell, J Lee, +10 authors, E Kilgour.
Oncoimmunology, 2019 Feb 08; 8(2). PMID: 30729066    Free PMC article.
HBV and HIV/HBV Infected Patients Have Distinct Immune Exhaustion and Apoptotic Serum Biomarker Profiles.
Mohamed Tarek M Shata, Enass A Abdel-Hameed, +6 authors, Kenneth E Sherman.
Pathog Immun, 2019 Mar 01; 4(1). PMID: 30815625    Free PMC article.
Successful Treatment of Myasthenia Gravis Following PD-1/CTLA-4 Combination Checkpoint Blockade in a Patient With Metastatic Melanoma.
Jan-Michael Werner, Viola Schweinsberg, +6 authors, Norbert Galldiks.
Front Oncol, 2019 Mar 05; 9. PMID: 30828569    Free PMC article.
miR-1271 enhances the sensitivity of colorectal cancer cells to cisplatin.
Huixiang Yao, Qun Sun, Jinshui Zhu.
Exp Ther Med, 2019 May 16; 17(6). PMID: 31086572    Free PMC article.
A pooled meta-analysis of PD-1/L1 inhibitors incorporation therapy for advanced non-small cell lung cancer.
Ning Wan, Bo Ji, +4 authors, Wenjie Huang.
Onco Targets Ther, 2019 Jul 16; 12. PMID: 31303759    Free PMC article.
Programmed death-ligand 1 signaling pathway involves in bladder cancer growth and progression.
Elena A Samishina, Ekaterina V Blinova, +5 authors, Olesia V Kit'ko.
J Carcinog, 2019 Jul 31; 18. PMID: 31360124    Free PMC article.
Achievements and futures of immune checkpoint inhibitors in non-small cell lung cancer.
Zhenbin Qiu, Zihao Chen, Chao Zhang, Wenzhao Zhong.
Exp Hematol Oncol, 2019 Aug 30; 8. PMID: 31463163    Free PMC article.
The evolving immuno-oncology landscape in advanced lung cancer: first-line treatment of non-small cell lung cancer.
Jia Li Low, Robert J Walsh, +2 authors, Ross A Soo.
Ther Adv Med Oncol, 2019 Sep 10; 11. PMID: 31497071    Free PMC article.
Renal adverse effects following the use of different immune checkpoint inhibitor regimens: A real-world pharmacoepidemiology study of post-marketing surveillance data.
Gang Chen, Yan Qin, +3 authors, Xue-Mei Li.
Cancer Med, 2020 Jul 29; 9(18). PMID: 32720449    Free PMC article.
The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives.
Danilo Rocco, Luigi D Gravara, Cesare Gridelli.
Curr Clin Pharmacol, 2019 Aug 11; 15(1). PMID: 31400270    Free PMC article.
[Immune-related Adverse Events Induced by ICIs in Advanced NSCLC:
A Meta-analysis and Systematic Review].
Qiaoxi Qin, Jiajin Wang, Hong Wang.
Zhongguo Fei Ai Za Zhi, 2020 Aug 06; 23(9). PMID: 32752580    Free PMC article.
Systematic Review.
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.
Chaoyue Su, Hui Wang, +7 authors, Jianye Zhang.
Front Oncol, 2020 Oct 20; 10. PMID: 33072580    Free PMC article.
Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Christian Borel, Alain C Jung, Mickaël Burgy.
Cancers (Basel), 2020 Sep 25; 12(9). PMID: 32967162    Free PMC article.
The risk of diarrhea and colitis in patients with lung cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
K Bishay, P Tandon, +2 authors, J D McCurdy.
Curr Oncol, 2020 Nov 12; 27(5). PMID: 33173388    Free PMC article.
Systematic Review.
Combinational immunotherapy based on immune checkpoints inhibitors in small cell lung cancer: is this the beginning to reverse the refractory situation?
Haoyue Guo, Yayi He, +7 authors, Caicun Zhou.
J Thorac Dis, 2020 Nov 20; 12(10). PMID: 33209440    Free PMC article.
The mechanism of and the association between interleukin-27 and chemotherapeutic drug sensitivity in lung cancer.
Bingdong Jiang, Wenbo Shi, +3 authors, Chuanming Bao.
Oncol Lett, 2020 Nov 27; 21(1). PMID: 33240420    Free PMC article.
First line Immunotherapy for Non-Small Cell Lung Cancer.
Nicola J Nasser, Miguel Gorenberg, Abed Agbarya.
Pharmaceuticals (Basel), 2020 Nov 12; 13(11). PMID: 33171686    Free PMC article.
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
Christopher R Heery, Geraldine O'Sullivan-Coyne, +15 authors, James L Gulley.
Lancet Oncol, 2017 Apr 05; 18(5). PMID: 28373007    Free PMC article.
Highly Cited.
PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
Maria Rita Gaiser, Michelle Bongiorno, Isaac Brownell.
Expert Rev Clin Pharmacol, 2018 Feb 27; 11(4). PMID: 29478343    Free PMC article.
Checkpoint inhibitors: What gastroenterologists need to know.
Monjur Ahmed.
World J Gastroenterol, 2019 Jan 10; 24(48). PMID: 30622372    Free PMC article.
Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
Houda Bahig, Francine Aubin, +14 authors, Philip Wong.
BMC Cancer, 2019 Jan 16; 19(1). PMID: 30642290    Free PMC article.
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma.
Margaret Ottaviano, Sabino De Placido, Paolo Antonio Ascierto.
Virchows Arch, 2019 Feb 13; 474(4). PMID: 30747264
Targeting Immune Checkpoints in Lung Cancer: Current Landscape and Future Prospects.
Long Long, Chen Zhao, +3 authors, Honglei Chen.
Clin Drug Investig, 2019 Feb 20; 39(4). PMID: 30778885
The safety and tolerability of combined immune checkpoint inhibitors (anti-PD-1/PD-L1 plus anti-CTLA-4): a systematic review and meta-analysis.
Lihu Gu, Parikshit Asutosh Khadaroo, +8 authors, Manman Chen.
BMC Cancer, 2019 Jun 12; 19(1). PMID: 31182049    Free PMC article.
Systematic Review.
Combination of CTLA-4 and PD-1 blockers for treatment of cancer.
Anand Rotte.
J Exp Clin Cancer Res, 2019 Jun 15; 38(1). PMID: 31196207    Free PMC article.
Highly Cited. Review.
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07.
Miso Kim, Bhumsuk Keam, +15 authors, Dae Seog Heo.
Thorac Cancer, 2020 Oct 08; 11(12). PMID: 33026712    Free PMC article.
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Ronan J Kelly, Jeeyun Lee, +21 authors, Geoffrey Y Ku.
Clin Cancer Res, 2019 Nov 05; 26(4). PMID: 31676670    Free PMC article.
The Advanced Practice Provider Perspective: Treating Patients With Immuno-Oncology Combination Therapy Across Tumor Types.
Brianna Hoffner, Renae Vaughn, Maureen Reed, Melinda S Weber.
J Adv Pract Oncol, 2019 May 01; 10(4). PMID: 33343985    Free PMC article.
Manipulating the Metabolism to Improve the Efficacy of CAR T-Cell Immunotherapy.
Marsha Pellegrino, Francesca Del Bufalo, +3 authors, Emmanuel de Billy.
Cells, 2020 Dec 31; 10(1). PMID: 33374128    Free PMC article.
A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
J Nehra, P A Bradbury, +16 authors, M Smoragiewicz.
Invest New Drugs, 2020 Feb 06; 38(5). PMID: 32020438
The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities.
Fatemeh Bayati, Mahsa Mohammadi, +3 authors, Ehsan Sharif-Paghaleh.
Front Immunol, 2021 Feb 02; 11. PMID: 33519807    Free PMC article.
Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer.
Darren J Schofield, Jennifer Percival-Alwyn, +18 authors, Michael Oberst.
MAbs, 2021 Jan 06; 13(1). PMID: 33397194    Free PMC article.
Immune checkpoint: The novel target for antitumor therapy.
Xianghu Jiang, Guohong Liu, Yirong Li, Yunbao Pan.
Genes Dis, 2019 Dec 20; 8(1). PMID: 33569511    Free PMC article.
Expression of Human Epidermal Growth Factor Receptor-2 Status and Programmed Cell Death Protein-1 Ligand Is Associated With Prognosis in Gastric Cancer.
Huifang Lv, Junling Zhang, +7 authors, Xiaobing Chen.
Front Oncol, 2021 Feb 19; 10. PMID: 33598422    Free PMC article.
Phage Display Technology as a Powerful Platform for Antibody Drug Discovery.
Kazuya Nagano, Yasuo Tsutsumi.
Viruses, 2021 Jan 29; 13(2). PMID: 33504115    Free PMC article.
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.
Jingjing Qu, Quanhui Mei, +4 authors, Jianying Zhou.
Ther Adv Med Oncol, 2021 Mar 02; 13. PMID: 33643442    Free PMC article.
COMMD1, from the Repair of DNA Double Strand Breaks, to a Novel Anti-Cancer Therapeutic Target.
Amila Suraweera, Pascal H G Duijf, +5 authors, Derek J Richard.
Cancers (Basel), 2021 Mar 07; 13(4). PMID: 33669398    Free PMC article.
Myasthenia gravis and concurrent myositis following PD-L1 checkpoint inhibitor for non-small cell lung cancer.
Chun Seng Phua, Ari Murad, +2 authors, Cecilia Cappelen-Smith.
BMJ Neurol Open, 2021 Mar 09; 2(1). PMID: 33681778    Free PMC article.
Analysis of the differences in lung cancer research trends between China and the United States based using project funding data.
Yuansheng Zheng, Yiwei Huang, +9 authors, Qun Wang.
Ann Transl Med, 2021 Mar 13; 9(3). PMID: 33708842    Free PMC article.
Delivery of gefitinib with an immunostimulatory nanocarrier improves therapeutic efficacy in lung cancer.
Dingwei Diao, Jianxue Zhai, +7 authors, Kaican Cai.
Transl Lung Cancer Res, 2021 Mar 16; 10(2). PMID: 33718033    Free PMC article.
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.
Yunes Panahi, Amir Hossein Mohammadzadeh, +3 authors, Amirhossein Sahebkar.
Adv Exp Med Biol, 2021 Mar 17; 1286. PMID: 33725344
Lessons From Immune Checkpoint Inhibitor Trials in Hepatocellular Carcinoma.
Raphael Mohr, Fabian Jost-Brinkmann, +7 authors, Christoph Roderburg.
Front Immunol, 2021 Apr 17; 12. PMID: 33859646    Free PMC article.
Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review.
Francesco Spagnolo, Andrea Boutros, +3 authors, Paola Queirolo.
BMC Cancer, 2021 Apr 19; 21(1). PMID: 33865350    Free PMC article.
Systematic Review.
Safety monitoring of two and four-weekly adjuvant durvalumab for patients with stage III NSCLC: implications for the COVID-19 pandemic and beyond.
Kroopa Joshi, Abdul Muhith, +7 authors, Anna Minchom.
Lung Cancer, 2021 May 10; 156. PMID: 33965281    Free PMC article.
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Roberto Ferrara, Martina Imbimbo, +4 authors, Virginie Westeel.
Cochrane Database Syst Rev, 2020 Dec 15; 12. PMID: 33316104    Free PMC article.
Systematic Review.
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Roberto Ferrara, Martina Imbimbo, +4 authors, Virginie Westeel.
Cochrane Database Syst Rev, 2021 May 01; 4. PMID: 33930176    Free PMC article.
Systematic Review.
Treatment-Related Serious Adverse Events of Immune Checkpoint Inhibitors in Clinical Trials: A Systematic Review.
Tao Ouyang, Yanyan Cao, +7 authors, Chuansheng Zheng.
Front Oncol, 2021 May 29; 11. PMID: 34046338    Free PMC article.
Systematic Review.
Durvalumab Plus Tremelimumab in Solid Tumors: A Systematic Review.
Caterina Arru, Maria Rosaria De Miglio, +4 authors, Panagiotis Paliogiannis.
Adv Ther, 2021 Jun 10; 38(7). PMID: 34105088    Free PMC article.
Systematic Review.
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
Kenneth K W To, Winnie Fong, William C S Cho.
Front Oncol, 2021 Jun 12; 11. PMID: 34113560    Free PMC article.
Immunotherapy in endometrial cancer: rationale, practice and perspectives.
Wenyu Cao, Xinyue Ma, +3 authors, Qing Zhang.
Biomark Res, 2021 Jun 18; 9(1). PMID: 34134781    Free PMC article.
Comparisons of Underlying Mechanisms, Clinical Efficacy and Safety Between Anti-PD-1 and Anti-PD-L1 Immunotherapy: The State-of-the-Art Review and Future Perspectives.
Yating Zhao, Liu Liu, Liang Weng.
Front Pharmacol, 2021 Jul 27; 12. PMID: 34305619    Free PMC article.
Inhibitors Targeting CDK9 Show High Efficacy against Osimertinib and AMG510 Resistant Lung Adenocarcinoma Cells.
Jaya Padmanabhan, Biswarup Saha, +3 authors, Srikumar Chellappan.
Cancers (Basel), 2021 Aug 08; 13(15). PMID: 34359807    Free PMC article.
The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines).
Andrea De Giglio, Alessandro Di Federico, +2 authors, Francesco Gelsomino.
Curr Oncol Rep, 2021 Aug 29; 23(11). PMID: 34453261    Free PMC article.
Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760).
Natasha B Leighl, Mary W Redman, +16 authors, David R Gandara.
J Immunother Cancer, 2021 Aug 26; 9(8). PMID: 34429332    Free PMC article.
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Robin Kate Kelley, Bruno Sangro, +21 authors, Ghassan K Abou-Alfa.
J Clin Oncol, 2021 Jul 23; 39(27). PMID: 34292792    Free PMC article.
Expression of p53 Protein Associates with Anti-PD-L1 Treatment Response on Human-Derived Xenograft Model of GATA3/CR5/6-Negative Recurrent Nonmuscular Invasive Bladder Urothelial Carcinoma.
Ekaterina Blinova, Elena Samishina, +16 authors, Andrew Kozdoba.
Int J Mol Sci, 2021 Sep 29; 22(18). PMID: 34576020    Free PMC article.
Research Progresses in Immunological Checkpoint Inhibitors for Breast Cancer Immunotherapy.
Wenxiang Zhang, Xiangyi Kong, +6 authors, Jing Wang.
Front Oncol, 2021 Oct 12; 11. PMID: 34631507    Free PMC article.
Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer.
Bin Wang, Hanfei Guo, +3 authors, Gang Zhao.
Cells, 2021 Oct 24; 10(10). PMID: 34685600    Free PMC article.
Reporting quality of randomized, controlled trials evaluating immunotherapy in lung cancer.
Jun Du, Yundi Zhang, +5 authors, Zhijie Wang.
Thorac Cancer, 2021 Aug 26; 12(20). PMID: 34432361    Free PMC article.
Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Abdulrazzak Zarifa, Juan Lopez-Mattei, +3 authors, Peter Y Kim.
Adv Exp Med Biol, 2022 Jan 02; 1342. PMID: 34972975
Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue.
Chin-Chou Wang, Kuo-Tung Huang, +6 authors, Meng-Chih Lin.
Thorac Cancer, 2021 Nov 30; 13(1). PMID: 34841687    Free PMC article.
Immune Checkpoint Inhibitor-Associated Colitis: From Mechanism to Management.
Liansha Tang, Jialing Wang, +4 authors, Xuelei Ma.
Front Immunol, 2022 Jan 08; 12. PMID: 34992611    Free PMC article.
Immune checkpoint-targeted antibodies: a room for dose and schedule optimization?
Christophe Maritaz, Sophie Broutin, +2 authors, Angelo Paci.
J Hematol Oncol, 2022 Jan 17; 15(1). PMID: 35033167    Free PMC article.
A universal in silico V(D)J recombination strategy for developing humanized monoclonal antibodies.
Yuan-Chin Hsieh, Jun-Min Liao, +11 authors, Tian-Lu Cheng.
J Nanobiotechnology, 2022 Feb 02; 20(1). PMID: 35101043    Free PMC article.
Risk of colitis in immune checkpoint inhibitors and in chemotherapy/placebo for solid tumors: a systematic review and meta-analysis.
Wei Wei, Yun Ding, Jiajia He, Jun Wu.
Transl Cancer Res, 2020 Jul 01; 9(7). PMID: 35117786    Free PMC article.
Navigational bronchoscopy specimens and PD-L1 expression: a retrospective study.
Hussein Asad, Timothy Saettele, +2 authors, Matthew Aboudara.
J Thorac Dis, 2022 Mar 15; 14(2). PMID: 35280465    Free PMC article.
Longitudinal changes of blood parameters and weight in inoperable stage III NSCLC patients treated with concurrent chemoradiotherapy followed by maintenance treatment with durvalumab.
J Guggenberger, S Kenndoff, +5 authors, F Manapov.
BMC Cancer, 2022 Mar 26; 22(1). PMID: 35331196    Free PMC article.
Multimodality Treatment of Pulmonary Sarcomatoid Carcinoma: A Review of Current State of Art.
Lin Zhang, Weihao Lin, +3 authors, Jie He.
J Oncol, 2022 Apr 05; 2022. PMID: 35368903    Free PMC article.
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Adel Naimi, Rebar N Mohammed, +11 authors, Ehsan Razeghian.
Cell Commun Signal, 2022 Apr 09; 20(1). PMID: 35392976    Free PMC article.
Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.
Yu-Wen Zhou, Qian Xu, +3 authors, Xue-Lei Ma.
Int J Ophthalmol, 2022 Apr 23; 15(4). PMID: 35450191    Free PMC article.
Review of Immune-Related Adverse Events (irAEs) in Non-Small-Cell Lung Cancer (NSCLC)-Their Incidence, Management, Multiorgan irAEs, and Rechallenge.
Raju Vaddepally, Rajiv Doddamani, +6 authors, Abhinav B Chandra.
Biomedicines, 2022 Apr 24; 10(4). PMID: 35453540    Free PMC article.
Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies.
Jesus Rodriguez-Pascual, Angel Ayuso-Sacido, Cristobal Belda-Iniesta.
Cancer Drug Resist, 2019 Dec 19; 2(4). PMID: 35582274    Free PMC article.
Immunotherapy in Penile Squamous Cell Carcinoma: Present or Future? Multi-Target Analysis of Programmed Cell Death Ligand 1 Expression and Microsatellite Instability.
Marco Montella, Rosalaura Sabetta, +18 authors, Federica Zito Marino.
Front Med (Lausanne), 2022 May 21; 9. PMID: 35592855    Free PMC article.